Provectus Biopharmaceuticals develops clinical-stage immunotherapy medicines built around rose bengal sodium, a synthetic small molecule in the halogenated xanthene family. News about PVCT centers on its PV-10 and PV-305 formulations, research publications, preclinical disease models, and clinical-program activity across oncology, dermatology, and ophthalmology.
Recurring updates also cover VisiRose, the company’s ocular-therapeutics subsidiary, and rose bengal photodynamic antimicrobial therapy for infectious keratitis and other eye infections. Additional company announcements address proof-of-concept work in wound healing, infectious disease, tissue repair, hematology, and vaccine-adjuvant research, along with annual-meeting and other public-company governance matters.
Provectus (OTCQB: PVCT) has completed enrollment of 12 patients in its Phase 1 study of PV-10, an injectable cancer immunotherapy targeting neuroendocrine tumors (NET) that are resistant to standard treatments. The therapy utilizes rose bengal disodium (RBD) to induce cell death in tumors. The primary focus is on safety, with secondary endpoints assessing response rates and receptor expressions. The company plans to engage with Australia’s Therapeutic Goods Administration for an end-of-phase meeting in Q1 2021.